Elicio Therapeutics Analysis: $89M Raised

Activate and amplify T cells against tumors; Develop vaccines for pancreatic ductal adenocarcinoma; Engineer immunotherapies for aggressive cancers; Utilize lymph nodes for targeted delivery; Enhance immune response in cancer patients

Elicio Therapeutics primarily focuses on developing cancer immunotherapies aimed at solid tumors, with a particular emphasis on challenging cancers such as pancreatic ductal adenocarcinoma (PDAC).

Elicio Therapeutics has developed several key innovations in the biotech sector, particularly in cancer immunotherapy. Their main products and innovations include:

1. AMP Platform: This platform utilizes advanced biomaterials technology combined with immunotherapeutic principles to create next-generation vaccines, immunomodulators, and adjuvants.
2. ELI-002: A personalized cancer vaccine that aims to enhance the immune response against tumors, particularly in challenging cancers like pancreatic ductal adenocarcinoma (PDAC).
3. Novel Immunotherapies: Elicio is focused on developing a pipeline of novel immunotherapies for the treatment of various cancers, leveraging their unique technology and research.

Elicio Therapeutics has established several significant partnerships and collaborations in the biotech industry, including:

1. A clinical supply agreement with Regeneron to evaluate the safety and efficacy of ELI-002 in combination with Libtayo (cemiplimab) for KRAS-driven tumors.
2. A collaboration with Natera to conduct a Phase I/II study of ELI-002 in pancreatic cancer.
3. A partnership with the Moffitt Cancer Center to study AMP-CD19 in combination with CD19 CAR-T cells.

These collaborations aim to enhance the development and application of Elicio's immunotherapy products.

Elicio Therapeutics primarily focuses on developing cancer immunotherapies aimed at solid tumors, with a particular emphasis on challenging cancers such as pancreatic ductal adenocarcinoma (PDAC).

Elicio Therapeutics recently secured $10 million in a registered direct offering. This funding round was announced approximately two months ago. The company is focused on developing cancer immunotherapies and aims to extend its operations through Q4 2025.

Elicio Therapeutics has reached alignment with the FDA regarding its ELI-002 product, indicating that they expect to file a Biologics License Application (BLA) if supported by a planned Phase 3 trial. This suggests that they are in the process of obtaining regulatory approval for ELI-002. Additionally, Elicio is developing other therapeutic cancer vaccines, including ELI-007 and ELI-008, which are also part of their pipeline but specific regulatory approvals for these products have not been detailed in the available sources.

Elicio Therapeutics has established several significant partnerships and collaborations in the biotech industry, including:

1. A clinical supply agreement with Regeneron to evaluate the safety and efficacy of ELI-002 in combination with Libtayo (cemiplimab) for KRAS-driven tumors.
2. A collaboration with Natera to conduct a Phase I/II study of ELI-002 in pancreatic cancer.
3. A partnership with the Moffitt Cancer Center to study AMP-CD19 in combination with CD19 CAR-T cells.

These collaborations aim to enhance the development and application of Elicio's immunotherapy products.